Stifel analyst Mathew Blackman raised the firm’s price target on Globus Medical (GMED) to $92 from $80 and keeps a Buy rating on the shares. Q3 “served as another, significant confirmation” of the firm’s thesis that the business is on more-solid footing today than most expected, the analyst tells investors. From here, the firm thinks estimates are “too low” and the multiple “can see 1-2 turns higher” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $92 from $80 at RBC Capital
- Globus Medical price target raised to $100 from $93 at Barclays
- Globus Medical price target raised to $85 from $70 at Canaccord
- Globus Medical price target raised to $100 from $80 at Piper Sandler
- Globus Medical price target raised to $87 from $78 at BTIG